Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163592

Authors

Dannel Yeo

Althea Bastian

Heidi Strauss

Payal Saxena

Peter Grimison

John E J Rasko

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type, characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited therapeutic response to standard chemotherapy. Circulating tumor cells (CTCs) are a rare subset of tumor cells found in the blood of cancer patients. CTCs has the potential utility for screening, early and definitive diagnosis, prognostic and predictive assessment, and offers the potential for personalized management. However, a gold-standard CTC detection and enrichment method remains elusive, hindering comprehensive comparisons between studies. In this review, we summarize data regarding the utility of CTCs at different stages of PDAC from early to metastatic disease and discuss the molecular profiling and culture of CTCs. The characterization of CTCs brings us closer to defining the specific CTC subpopulation responsible for metastasis with the potential to uncover new therapies and more effective management options for PDAC.

Citing Articles

A type of pancreatic cancer cells form cell clusters from a solitary condition in a primary ciliogenesis-dependent manner.

Shirakawa K, Nakazato R, Hara T, Uemura K, Ijaz F, Takahashi S Med Mol Morphol. 2025; .

PMID: 40069423 DOI: 10.1007/s00795-025-00428-0.

Cancer-associated macrophage-like cells as a prognostic biomarker in solid tumors.

Pirrello A, Killingsworth M, Spring K, Rasko J, Yeo D J Liq Biopsy. 2025; 6:100275.

PMID: 40027315 PMC: 11863711. DOI: 10.1016/j.jlb.2024.100275.

Plasma treatment can efficiently increase the attachment of pancreatic circulatory tumor cells to the surface.

Mahdian S, Mahmoudi-Aznaveh A, Mousavi S, Larijani B, Azizi Z, Javar H Discov Oncol. 2025; 16(1):222.

PMID: 39982607 PMC: 11845332. DOI: 10.1007/s12672-025-01988-4.

Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma.

Gotze J, Meissner K, Pereira-Veiga T, Belloum Y, Schneegans S, Kropidlowski J J Exp Clin Cancer Res. 2025; 44(1):14.

PMID: 39815324 PMC: 11737273. DOI: 10.1186/s13046-024-03262-x.

The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer.

Cox M, Vitello D, Chawla A J Gastrointest Cancer. 2025; 56(1):44.

PMID: 39808248 DOI: 10.1007/s12029-024-01129-0.

References

Gach P, Attayek P, Whittlesey R, Yeh J, Allbritton N . Micropallet arrays for the capture, isolation and culture of circulating tumor cells from whole blood of mice engrafted with primary human pancreatic adenocarcinoma. Biosens Bioelectron. 2013; 54:476-83. PMC: 3947965. DOI: 10.1016/j.bios.2013.11.019. View

Soeth E, Grigoleit U, Moellmann B, Roder C, Schniewind B, Kremer B . Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005; 131(10):669-76. DOI: 10.1007/s00432-005-0008-1. View

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C . Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017; 117(7):1017-1025. PMC: 5625666. DOI: 10.1038/bjc.2017.250. View

Seppala T, Zimmerman J, Sereni E, Plenker D, Suri R, Rozich N . Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Ann Surg. 2020; 272(3):427-435. PMC: 7901605. DOI: 10.1097/SLA.0000000000004200. View

Dipardo B, Winograd P, Court C, Tomlinson J . Pancreatic cancer circulating tumor cells: applications for personalized oncology. Expert Rev Mol Diagn. 2018; 18(9):809-820. DOI: 10.1080/14737159.2018.1511429. View

Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

Pishvaian M, Blais E, Brody J, Lyons E, DeArbeloa P, Hendifar A . Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020; 21(4):508-518. PMC: 7453743. DOI: 10.1016/S1470-2045(20)30074-7. View

Khoo B, Grenci G, Lim Y, Lee S, Han J, Lim C . Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device. Nat Protoc. 2017; 13(1):34-58. DOI: 10.1038/nprot.2017.125. View

Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B . Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers (Basel). 2019; 11(11). PMC: 6895979. DOI: 10.3390/cancers11111659. View

10.

Sharma G, Okada Y, Von Hoff D, Goel A . Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol. 2020; 75:153-168. PMC: 8035348. DOI: 10.1016/j.semcancer.2020.10.001. View

11.

Hugenschmidt H, Labori K, Borgen E, Brunborg C, Schirmer C, Thomas Seeberg L . Preoperative CTC-Detection by CellSearch Is Associated with Early Distant Metastasis and Impaired Survival in Resected Pancreatic Cancer. Cancers (Basel). 2021; 13(3). PMC: 7865868. DOI: 10.3390/cancers13030485. View

12.

Groot V, Gemenetzis G, Blair A, Rivero-Soto R, Yu J, Javed A . Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019; 269(6):1154-1162. PMC: 6191366. DOI: 10.1097/SLA.0000000000002734. View

13.

Chang M, Chang Y, Chen J, Jeng Y, Yang C, Tien Y . Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem. 2016; 62(3):505-13. DOI: 10.1373/clinchem.2015.248260. View

14.

Michelakos T, Pergolini I, Fernandez-Del Castillo C, Honselmann K, Cai L, Deshpande V . Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2017; 269(4):733-740. DOI: 10.1097/SLA.0000000000002600. View

15.

Kulemann B, Rosch S, Seifert S, Timme S, Bronsert P, Seifert G . Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Sci Rep. 2017; 7(1):4510. PMC: 5495768. DOI: 10.1038/s41598-017-04601-z. View

16.

Lu Y, Wang P, Peng J, Wang X, Zhu Y, Shen N . Meta-analysis Reveals the Prognostic Value of Circulating Tumour Cells Detected in the Peripheral Blood in Patients with Non-Metastatic Colorectal Cancer. Sci Rep. 2017; 7(1):905. PMC: 5430457. DOI: 10.1038/s41598-017-01066-y. View

17.

Duffy M, Sturgeon C, Lamerz R, Haglund C, Holubec V, Klapdor R . Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2009; 21(3):441-447. DOI: 10.1093/annonc/mdp332. View

18.

Mishra A, Dubash T, Edd J, Jewett M, Garre S, Karabacak N . Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells. Proc Natl Acad Sci U S A. 2020; 117(29):16839-16847. PMC: 7382214. DOI: 10.1073/pnas.2006388117. View

19.

Poruk K, Valero 3rd V, He J, Ahuja N, Cameron J, Weiss M . Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas. 2017; 46(7):943-947. DOI: 10.1097/MPA.0000000000000869. View

20.

Rodriguez-Lee M, Kolatkar A, McCormick M, Dago A, Kendall J, Carlsson N . Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay. Arch Pathol Lab Med. 2017; 142(2):198-207. PMC: 7679174. DOI: 10.5858/arpa.2016-0483-OA. View